The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis

Archives of Medical Science

Volumn 11, Issue 3, 2015, Pages 584-590

  Shen, Hong ^a   Min, Rui ^a   Tan, Qi ^a   Xie, Weiping ^a   Wang, Hong ^a   Pan, Hongqiu ^b   Zhang, Li ^c   Xu, Hongtao ^d   Zhang, Xia ^e   Dai, Jianzhong ^f  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Third Hospital of Zhenjiang City   (China)

^c The Second People s Hospital of Lianyungang   (China)

^d TAIZHOU PEOPLE S HOSPITAL   (China)

^e NANJING CHEST HOSPITAL   (China)

^f The Sixth People Hospital of Nantong   (China)

Author keywords

CD4+CD25+ T cells; Immunotherapy; Interleukin 2; Multidrug resistant tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RECOMBINANT HUMAN INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CD4+ CD25+ T LYMPHOCYTE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERPIGMENTATION; IMMUNOTHERAPY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PAIN; PNEUMONIA; SINGLE DRUG DOSE; SPUTUM CULTURE; SPUTUM SMEAR; T LYMPHOCYTE SUBPOPULATION; THORAX RADIOGRAPHY;

EID: 84932121024     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.52362     Document Type: Article

References (30)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3.Geneva, Switzerland:WHO,2010. http://www.who.int/tb/publications/2010/mdrtb2010report-executive-summary.pdf. Accessed July 2012.
2. Mercedes GJ. Immunity to TB and targets for immunotherapy. Immunotherapy 2012; 4: 187-99.
3. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205: S325-34.
4. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30: 769-82.
5. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann Rev Pathol Mech Dis 2012; 7: 353-84.
6. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculoisis: from bench to beside. Respirogy 2010; 15: 433-50.
7. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002; 32: 1605-13.
8. Tan Q, Xie WP, Min R, et al. Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 2012; 31: 1233-42.
9. Shahemabadi AS, Hosseini AZ, Shaghsempour S, Rayani M, Pouramiri M. Evaluation of T cell immune responses in multi-drug-resistant tuberculosis (MDR-TB) patients to Mycobacterium tuberculosis total lipid antigens. Clin Exp Immunol 2007; 149: 285-94.
10. Geffner L, Yokobori N, Basile J, et al. Patients with multidrug-resistant tuberculosis display impaired Thl responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains. Infect Immun 2009; 77: 5025-34.
11. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78: 195-203.
12. Chu NH, Zhu LZ, Yie ZZ, et al. A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis. Chin J Tuberc Respir Dis 2003; 26: 548-51.
13. Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 185-91.
14. Johnson BJ, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low-lose IL-2 and multidrug therapy. Cytokines Mol Ther 1995; 1: 185-96.
15. Barnes PF. Immunotherapy for tuberculosis: wave of the future or tilting at windmills? Am J Resp Crit Care 2003; 168: 142-3.
16. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immun 2012; 12: 180-90.
17. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003; 74: 961-5.
18. de la Rosa M, Rutz S, Dominger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34: 2480-8.
19. Brandenburg S, Takahashi T, de la Rosa M, et al. IL-2 induces in vivo suppression by CD4+CD25+Foxp3+regulatory T cells. Eur J Immunol 2008; 38: 1643-53.
20. Kiran B, Cagatay T, Clark P, et al. Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis? Arch Med Sci 2010; 6: 77-82.
21. Smith SM, Dockrell HM. Role of CD8+ T cells in mycobacterial infections. Immunol Cell Biol 2000; 78: 325-33.
22. Rook GA, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196: 191-8.
23. Mills-Kingston HG. Regulatory T cvells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
24. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
25. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006; 173: 803-10.
26. Hougardy JM, Place S, Hildebrand M, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007; 176: 409-16.
27. Xu CC, Xie WP, Dai GQ, Tan Q, Min R, Wang H. Change of the peripheral blood CD4+CD25+Foxp3+T cells in patients with multidrug-resistant tuberculosis. Acta Univ Med Nanjing 2011; 31: 419-21.
28. He XY, Xiao L, Chen HB, et al. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis 2010; 29: 643-50.
29. Ribeiro-Rodrigues R, Resende Co T, Rojas R, et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006; 144: 25-34.
30. Ciebiada M, Kasztalska K, Gorska-Ciebiada M, Barylski M, Gorski P. Expression of IL-7 receptor in human peripheral regulatory T cells. Arch Med Sci 2013; 9: 555-60.